Aromatase inhibitor-associated bone loss and its management with bisphosphonates in patients with breast cancer

References

• MortimerJEManaging the toxicities of the aromatase inhibitorsCurr Opin Obstet Gynecol201022566020019610
   PubMed Web of Science ®Google Scholar
• HadjiPAromatase inhibitor-associated bone loss in breast cancer patients is distinct from postmenopausal osteoporosisCrit Rev Oncol Hematol200969738218757208
   PubMed Web of Science ®Google Scholar
• FolkestadLBjarnasonNHBjerregaardJKBrixenKThe effect of aromatase inhibitors on bone metabolismBasic Clin Pharmacol Toxicol200810431019152547
   PubMed Web of Science ®Google Scholar
• MillerWRBartlettJBrodieAMAromatase inhibitors: are there differences between steroidal and nonsteroidal aromatase inhibitors and do they matter?Oncologist20081382983718695261
   PubMed Web of Science ®Google Scholar
• JanniWHeppPAdjuvant aromatase inhibitor therapy: outcomes and safetyCancer Treat Rev20103624926120133065
   PubMed Web of Science ®Google Scholar
• ContePFrassoldatiAAromatase inhibitors in the adjuvant treatment of postmenopausal women with early breast cancer: putting safety into perspectiveBreast J200713283517214790
   PubMed Web of Science ®Google Scholar
• OzairSIqbalSEfficacy and safety of aromatase inhibitors in early breast cancerExpert Opin Drug Saf2008754755818759707
   PubMed Web of Science ®Google Scholar
• MacedoLFSabnisGBrodieAAromatase inhibitors and breast cancerAnn N Y Acad Sci2009115516217319250202
   PubMed Web of Science ®Google Scholar
• GeislerJAromatase inhibitors: from bench to bedside and backBreast Cancer200815172618224389
   PubMed Web of Science ®Google Scholar
• GeislerJKingNDowsettMInfluence of anastrozole (Arimidex), a selective, non-steroidal aromatase inhibitor, on in vivo aromatisation and plasma oestrogen levels in postmenopausal women with breast cancerBr J Cancer199674128612918883419
   PubMed Web of Science ®Google Scholar
• GeislerJKingNAnkerGIn vivo inhibition of aromatization by exemestane, a novel irreversible aromatase inhibitor, in postmenopausal breast cancer patientsClin Cancer Res19984208920939748124
   PubMed Web of Science ®Google Scholar
• GeislerJHaynesBAnkerGDowsettMLonningPEInfluence of letrozole and anastrozole on total body aromatization and plasma estrogen levels in postmenopausal breast cancer patients evaluated in a randomized, cross-over studyJ Clin Oncol20022075175711821457
   PubMed Web of Science ®Google Scholar
• DowsettMJonesAJohnstonSRJacobsSTrunetPSmithIEIn vivo measurement of aromatase inhibition by letrozole (CGS 20267) in postmenopausal patients with breast cancerClin Cancer Res19951151115159815951
   PubMed Web of Science ®Google Scholar
• BursteinHJGriggsJJPrestrudAATeminSAmerican Society of Clinical Oncology clinical practice guidelines: update on adjuvant endocrine therapy for women with hormone receptor-positive breast cancerJ Clin Oncol2010283784379620625130
   PubMed Web of Science ®Google Scholar
• GoldhirschAIngleJNGelberRDThresholds for therapies: highlights of the St Gallen International Expert Consensus on the Primary Therapy of Early Breast Cancer 2009Ann Oncol2009201319132919535820
   PubMed Web of Science ®Google Scholar
• HowellACuzickJBaumMResults of the ATAC (Arimidex, Tamoxifen, Alone or in Combination) trial after completion of 5 years’ adjuvant treatment for breast cancerLancet2005365606215639680
   PubMed Web of Science ®Google Scholar
• ThürlimannBKeshaviahACoatesASA comparison of letrozole and tamoxifen in postmenopausal women with early breast cancerN Engl J Med20053532747275716382061
   PubMed Web of Science ®Google Scholar
• CoatesASKeshaviahAThürlimannBFive years of letrozole compared with tamoxifen as initial adjuvant therapy for postmenopausal women with endocrine-responsive early breast cancer: update of study BIG1-98J Clin Oncol20072548649217200148
   PubMed Web of Science ®Google Scholar
• MouridsenHGiobbie-HurderAGoldhirschALetrozole therapy alone or in sequence with tamoxifen in women with breast cancerN Engl J Med200736176677619692688
   PubMed Web of Science ®Google Scholar
• BoccardoFRubagottiAPuntoniMSwitching to anastrozole versus continued tamoxifen treatment of early breast cancer: preliminary results of the Italian Tamoxifen Anastrozole TrialJ Clin Oncol2005235138514716009955
   PubMed Web of Science ®Google Scholar
• CoombesRCHallEGibsonLJA randomized trial of exemestane after two to three years of tamoxifen therapy in postmenopausal women with primary breast cancerN Engl J Med20043501081109215014181
   PubMed Web of Science ®Google Scholar
  Erratum in:New Engl J Med20043512461
   Google Scholar
• CoombesRCKilburnLSSnowdonCFSurvival and safety of exemestane versus tamoxifen after 2–3 years’ tamoxifen treatment (Intergroup Exemestane Study): a randomised controlled trialLancet200736955957017307102
   PubMed Web of Science ®Google Scholar
  Erratum in:Lancet200736990617368151
   PubMedGoogle Scholar
• JonesSESeynaeveCHasenburgAResults of the first planned analysis of the TEAM (tamoxifen exemestane adjuvant multinational) prospective randomized phase III trial in hormone sensitive postmenopausal early breast cancerCancer Res200969Suppl 267S Abstract 15
   Web of Science ®Google Scholar
• ChlebowskiRCuzickJAmakyeDClinical perspectives on the utility of aromatase inhibitors for the adjuvant treatment of breast cancerBreast200918Suppl 2S1S1119712865
   PubMedGoogle Scholar
• SaphnerTTormeyDCGrayRAnnual hazard rates of recurrence for breast cancer after primary therapyJ Clin Oncol199614273827468874335
   PubMed Web of Science ®Google Scholar
• MansellJMonypennyIJSkeneAIPatterns and predictors of early recurrence in postmenopausal women with estrogen receptor-positive early breast cancerBreast Cancer Res Treat2009117919819112615
   PubMed Web of Science ®Google Scholar
• LameratoLHavstadSGandhiSJonesDChlebowskiRBreast cancer recurrence and related mortality in US pts with early breast cancerJ Clin Oncol200523Suppl 1662S Abstract 738
   Web of Science ®Google Scholar
• BaumMBuzdarACuzickJAnastrozole alone or in combination with tamoxifen versus tamoxifen alone for adjuvant treatment of postmenopausal women with early-stage breast cancer: results of the ATAC (Arimidex, Tamoxifen Alone or in Combination) trial efficacy and safety update analysesCancer2003981802181014584060
   PubMed Web of Science ®Google Scholar
• GossPEIngleJNMartinoSRandomised trial of letrozole following tamoxifen as extended adjuvant therapy in receptor-positive breast cancer: updated findings from NCIC CTG MA.17J Natl Cancer Inst2005971262127116145047
   PubMed Web of Science ®Google Scholar
• JakeszRJonatWGnantMSwitching of postmenopausal women with endocrine-responsive early breast cancer to anastrozole after 2 years’ adjuvant tamoxifen: combined results of ABCSG trial 8 and ARNO 95 trialLancet200536645546216084253
   PubMed Web of Science ®Google Scholar
• ForbesJFCuzickJBuzdarAEffect of anastrozole and tamoxifen as adjuvant treatment for early-stage breast cancer: 100-month analysis of the ATAC trialLancet Oncol20089455318083636
   PubMed Web of Science ®Google Scholar
• JonatWHilpertFKaufmannMAromatase inhibitors: a safety comparisonExpert Opin Drug Saf2007616517417367262
   PubMed Web of Science ®Google Scholar
• ReaDHasenburgASeynaeveCFive years of exemestane as initial therapy compared to tamoxifen followed by exemestane for five years: the TEAM trial, a prospective, randomized, phase iii trial in postmenopausal women with hormone-sensitive early breast cancerCancer Res200969SupplS24
   Google Scholar
• HadjiPAaproMSBodyJJPractical guidance for the management of aromatase inhibitor-associated bone lossAnn Oncol2008191407141618448451
   PubMed Web of Science ®Google Scholar
• ClunieGPClarkAMortimerCJEvaluating bone health in women with oestrogen receptor positive breast cancer (ERBC) starting aromatase inhibitorsEur J Surg Oncol20093547548018950981
   PubMed Web of Science ®Google Scholar
• HadjiPZillerMKiebackDGEffects of exemestane and tamoxifen on bone health within the Tamoxifen Exemestane Adjuvant Multicentre (TEAM) trial: results of a German, 12-month, prospective, randomised substudyAnn Oncol2009201203120919218306
   PubMed Web of Science ®Google Scholar
• DelaneyMFStrategies for the prevention and treatment of osteoporosis during early postmenopauseAm J Obstet Gynecol2006194Suppl 2S12S2316448872
   PubMed Web of Science ®Google Scholar
• GibsonKO’BryantCLScreening and management of osteoporosis in breast cancer patients on aromatase inhibitorsJ Oncol Pharm Pract20081413914518719068
   PubMedGoogle Scholar
• GralowJRBiermannJSFarookiANCCN Task Force Report: Bone Health in Cancer CareJ Natl Compr Canc Netw20097Suppl 3S1S32S33S3519555589
   PubMed Web of Science ®Google Scholar
• GeislerJLonningPEImpact of aromatase inhibitors on bone health in breast cancer patientsJ Steroid Biochem Mol Biol201011829429919833206
   PubMed Web of Science ®Google Scholar
• BertoldoFPancheriSZenariSBoldiniSEmerging drugs for the management of cancer treatment induced bone lossExpert Opin Emerg Drugs20101532334220377485
   PubMed Web of Science ®Google Scholar
• YamamotoDSVialePHUpdate on identifying and managing osteoporosis in women with breast cancerClin J Oncol Nurs200913E18E2919793700
   PubMed Web of Science ®Google Scholar
• RugoHSThe breast cancer continuum in hormone-receptor-positive breast cancer in postmenopausal women: evolving management options focusing on aromatase inhibitorsAnn Oncol200819162717693420
   PubMed Web of Science ®Google Scholar
• EastellRHannonRACuzickJClackGAdamsJEEffect of anastrozole on bone density and bone turn over: results of the ‘Arimidex’ (anastrozole), Tamoxifen, Alone or in Combination (ATAC) studyJ Bone Miner Res200217Suppl 1S165
   Google Scholar
• GnantMHausmaningerHSamoniggHChanges in bone mineral density caused by anastrozole or tamoxifen in combination with goserelin (+/− zoledronate as adjuvant treatment for hormone receptor-positive premenopausal breast cancer: results of a randomized multicenter trialBreast Cancer Res Treat200276Suppl 1S31 Abstract 12
   Google Scholar
• McCaigFMRenshawLWilliamsLA randomised study of the effects of anastrozole (A), letrozole (L) and exemestane (E) on bone turnoverBreast Cancer Res Treat200911964365119941160
   PubMedGoogle Scholar
• McCloskeyEHannonRLaknerGClackGMiyamotoAEastellRInteraction between body mass index and bone turnover during aromatase inhibition: evidence from the letrozole (L), exemestane (E), and anastrozole (A) pharmacodynamics (LEAP) trialJ Clin Oncol200725Suppl 1817S Abstract 560
   Web of Science ®Google Scholar
• ReidDMPrevention of osteoporosis after breast cancerMaturitas2009644819709826
   PubMed Web of Science ®Google Scholar
• ColemanREBodyJJGralowJRLiptonABone loss in patients with breast cancer receiving aromatase inhibitors and associated treatment strategiesCancer Treat Rev200834Suppl 1S31S4218486346
   PubMedGoogle Scholar
• BundredNJCampbellIDDavidsonNEffective inhibition of aromatase inhibitor-associated bone loss by zoledronic acid in postmenopausal women with early breast cancer receiving adjuvant letrozole: ZO-FAST Study resultsCancer20081121001101018205185
   PubMed Web of Science ®Google Scholar
• AbdulhaqHGeyerCSafety of adjuvant endocrine therapy in postmenopausal women with breast cancerAm J Clin Oncol20083159560519060594
   PubMed Web of Science ®Google Scholar
• SaadFAdachiJDBrownJPCancer treatment-induced bone loss in breast and prostate cancerJ Clin Oncol2008265465547618955443
   PubMed Web of Science ®Google Scholar
• ChapurlatRDBauerDCCummingsSRAssociation between endogenous hormones and sex hormone-binding globulin and bone turnover in older women: study of osteoporotic fracturesBone20012938138711595622
   PubMed Web of Science ®Google Scholar
• GarneroPSornay-RenduEClaustratBDelmasPDBiochemical markers of bone turnover, endogenous hormones and the risk of fractures in postmenopausal women: the OFELY studyJ Bone Miner Res2000151526153610934651
   PubMed Web of Science ®Google Scholar
• RogersASalehGHannonRAGreenfieldDEastellRCirculating estradiol and osteoprotegerin as determinants of bone turnover and bone density in postmenopausal womenJ Clin Endocrinol Metab2002874470447512364420
   PubMed Web of Science ®Google Scholar
• EttingerBPressmanASklarinPBauerDCCauleyJACummingsSRAssociations between low levels of serum estradiol, bone density, and fractures among elderly women: the study of osteoporotic fracturesJ Clin Endocrinol Metab199883223922439661589
   PubMed Web of Science ®Google Scholar
• CummingsSRBrownerWSBauerDEndogenous hormones and the risk of hip and vertebral fractures among older women. Study of Osteoporotic Fractures Research GroupN Engl J Med19983397337389731089
   PubMed Web of Science ®Google Scholar
• ChapurlatRDGarneroPBreartGMeunierPJDelmasPDSerum estradiol and sex hormone-binding globulin and the risk of hip fracture in elderly women: the EPIDOS studyJ Bone Miner Res2000151835184110977003
   PubMed Web of Science ®Google Scholar
• PerezEASafety profiles of tamoxifen and the aromatase inhibitors in adjuvant therapy of hormone-responsive early breast cancerAnn Oncol200718Suppl 8viii26viii3517890211
   PubMed Web of Science ®Google Scholar
• EastellRHannonRACuzickJEffect of an aromatase inhibitor on BMD and bone turnover markers: 2-year results of the Anastrozole, Tamoxifen, Alone or in Combination (ATAC) trial (182332030)J Bone Miner Res2006211215122316869719
   PubMed Web of Science ®Google Scholar
• BerryJAre all aromatase inhibitors the same? A review of controlled clinical trials in breast cancerClin Ther2005271671168416368441
   PubMed Web of Science ®Google Scholar
• RabaglioMSunZPriceKNBone fractures among postmenopausal patients with endocrine-responsive early breast cancer treated with 5 years of letrozole or tamoxifen in the BIG 1-98 trialAnn Oncol2009201489149819474112
   PubMed Web of Science ®Google Scholar
• ColemanREBanksLMGirgisSISkeletal effects of exemestane on bone-mineral density, bone biomarkers, and fracture incidence in postmenopausal women with early breast cancer participating in the Intergroup Exemestane Study (IES): a randomized controlled studyLancet Oncol2007811912717267326
   PubMed Web of Science ®Google Scholar
• HadjiPZillerMKiebackDGThe effect of exemestane or tamoxifen on markers of bone turnover: results of a German sub-study of the Tamoxifen Exemestane Adjuvant Multicentre (TEAM) trialBreast20091815916419364653
   PubMed Web of Science ®Google Scholar
• PantSShapiroCLAromatase inhibitor-associated bone loss: clinical considerationsDrugs2008682591260019093701
   PubMed Web of Science ®Google Scholar
• YamamotoYIwaseHSafety profiles of aromatase inhibitors and selective estrogen-receptor modulators in the treatment of early breast cancerInt J Clin Oncol20081338439418946748
   PubMed Web of Science ®Google Scholar
• HadjiPAaproMSBodyJJManagement of aromatase inhibitor-associated bone loss in postmenopausal women with breast cancer: practical guidance for prevention and treatmentAnn Oncol2011222546255521415233
   PubMed Web of Science ®Google Scholar
• BundredNJAromatase inhibitors and bone healthCurr Opin Obstet Gynecol200921606719125005
   PubMed Web of Science ®Google Scholar
• AaproMAbrahamssonPABodyJJGuidance on the use of bisphosphonates in solid tumours: recommendations of an international expert panelAnn Oncol20081942043217906299
   PubMed Web of Science ®Google Scholar
• HadjiPZillerMAlbertUSKalderMAssessment of fracture risk in women with breast cancer using current vs emerging guidelinesBr J Cancer201010264565020087347
   PubMed Web of Science ®Google Scholar
• BrufskyAMBossermanLDCaradonnaRRZoledronic acid effectively prevents aromatase inhibitor-associated bone loss in postmenopausal women with early breast cancer receiving adjuvant letrozole: Z-FAST study 36-month follow-up resultsClin Breast Cancer20099778519433387
   PubMed Web of Science ®Google Scholar
• BrufskyAHarkerWGBeckJTThe effect of zoledronic acid on aromatase inhibitor-associated bone loss in postmenopausal women with early breast cancer receiving adjuvant letrozole: the Z-FAST study 5-year final follow upPresented at the 32nd Annual San Antonio Breast Cancer Symposium (SABCS)San Antonio, TXDecember 9–132009 Abstract 4083
   Google Scholar
• DeBoerRBundredNEidtmannHThe effect of zoledronic acid on aromatase inhibitor associated bone loss in postmenopausal women with early breast cancer receiving adjuvant letrozole: the ZO-FAST study 5-year final follow-ppPresented at the 33rd Annual San Antonio Breast Cancer Symposium (SABCS)San Antonio, TXDecember 8–122010 Abstract P5-11-01
   Google Scholar
• ColemanRGnantMNew results from the use of bisphosphonates in cancer patientsCurr Opin Support Palliat Care2009321321819561507
   PubMedGoogle Scholar
• JohnstonSRDowsettMAromatase inhibitors for breast cancer: lessons from the laboratoryNat Rev Cancer2003382183114668813
   PubMed Web of Science ®Google Scholar
• GnantMClézardinPDirect and indirect anticancer activity of bisphosphonates: a brief review of published literatureCancer Treat Rev10 72011 [Epub ahead of print.]
   PubMed Web of Science ®Google Scholar
• GnantMEidtmannHThe anti-tumour effect of bisphosphonates ABCSG-12, ZO-FAST and more…Crit Rev Oncol Hematol201074Suppl 1S2S620427029
   PubMedGoogle Scholar
• CartenìGBordonaroRGiottaFEfficacy and safety of zoledronic acid in patients with breast cancer metastatic to bone: a multicenter clinical trialOncologist20061184184816880243
   PubMed Web of Science ®Google Scholar
• AbrahamJZoledronic acid improves disease-free survival in hormone-responsive early breast cancerCommunity Oncol200961113
   Google Scholar
• ColemanREMarshallHCameronDAZURE InvestigatorsBreast-cancer adjuvant therapy with zoledronic acidN Engl J Med20113651396140521995387
   PubMed Web of Science ®Google Scholar
• ColemanRBundredNde BoerRImpact of zoledronic acid in postmenopausal women with early breast cancer receiving adjuvant letrozole: Z-FAST, ZO-FAST, and E-ZO-FASTPresented at the 32nd Annual San Antonio Breast Cancer Symposium (SABCS)San Antonio, TXDecember 9–132009 Abstract 4082
   Google Scholar
• HinesSLSloanJAAthertonPJZoledronic acid for treatment of osteopenia and osteoporosis in women with primary breast cancer undergoing adjuvant aromatase inhibitor therapyBreast201019929620079640
   PubMed Web of Science ®Google Scholar
• NievesJWBarrett-ConnorESirisESCalcium and vitamin D intake influence bone mass, but not short-term fracture risk, in Caucasian postmenopausal women from the National Osteoporosis Risk Assessment (NORA) studyOsteoporosis Int200819673679
   PubMed Web of Science ®Google Scholar
• BoonenSLipsPBouillonRBischoff-FerrariHAVanderschuerenDHaentjensPNeed for additional calcium to reduce the risk of hip fracture with vitamin D supplementation: evidence from a comparative metaanalysis of randomized controlled trialsJ Clin Endocrinol Metabol20079214151423
   PubMed Web of Science ®Google Scholar
• JacksonRDLaCroixAZGassMCalcium plus vitamin D supplementation and the risk of fracturesN Engl J Med200635466968316481635
   PubMed Web of Science ®Google Scholar
  Erratum in:N Engl J Med20093541102
   Google Scholar
• KemmlerWEngelkeKvon StengelSWeineckJLauberDKalenderWALong-term four-year exercise has a positive effect on menopausal risk factors: the Erlangen Fitness Osteoporosis Prevention StudyJ Strength Cond Res20072123223917313298
   PubMed Web of Science ®Google Scholar
• LipsPBouillonRvan SchoorNMReducing fracture risk with calcium and vitamin DClin Endocrinol (Oxford)200973277285
   Web of Science ®Google Scholar
• KanisJADiagnosis of osteoporosisOsteoporosis Int19977Suppl 3S108S116
   PubMed Web of Science ®Google Scholar
• ShapiroCLManolaJLeboffMOvarian failure after adjuvant chemotherapy is associated with rapid bone loss in women with early-stage breast cancerJ Clin Oncol2001193306331111454877
   PubMed Web of Science ®Google Scholar
• PowlesTJHickishTKanisJATidyAAshleySEffect of tamoxifen on bone mineral density measured by dual-energy x-ray absorptiometry in healthy premenopausal and postmenopausal womenJ Clin Oncol19961478848558225
   PubMed Web of Science ®Google Scholar